Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


The McDonald Criteria, used for the diagnosis of multiple sclerosis (MS), has been revised by a 30-member international panel of MS experts co-chaired by Jeffrey Cohen, MD (Cleveland Clinic) and...

The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using beta interferons and glatiramer acetate for the treatment of multiple...

Medday, the makers of Biotin have formally withdrawn their application for EMA (European Medicines Agency) marketing authorisation for progressive MS drug Qizenday.

Qizenday is a capsule...

Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or...

A study of around 7,000 people with MS in North America has assessed how diet quality is associated with disability.

Researchers at John Hopkins School of Medicine used the NARCOMS (North...

Insights into how the body clock and time of day influence immune responses have been revealed in a study published in the journal...

New international research finds that people living with multiple sclerosis (MS) prioritise slowing disease progression when considering treatment choices. People with MS want therapies that...

Two researchers in the department of anatomy and cell biology in the University of Illinois at Chicago (UIC) College of Medicine have received a seed grant to develop a new drug delivery method...

Active Biotech drug, laquinimod has failed a phase II trial in primary progressive MS.

Laquinimod a once-daily oral drug targets neurodegeneration and inflammation with a novel mechanism of...

Early medical intervention for the treatment of multiple sclerosis (MS) has been debated by experts for a number of years, with the likes of Gavin Giovannoni a Professor at Barts and the London...

Pages

Live Chat Software by Click4Assistance UK